Medigen Biotechnology (ROCO:3176) Common Stock: NT$1,393 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3176 Medigen Biotechnology Corp ROCO:3176
54 GF Score
Price NT$34.15
GF Value NT$49.78
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medigen Biotechnology Common Stock?

Medigen Biotechnology ROCO:3176 +1.19% 54 Common Stock is NT$1,393 Mil as of Dec. 2025. GuruFocus rates ROCO:3176 with a GF Score™ of 54/100 and a GF Value™ of NT$49.78 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Medigen Biotechnology's quarterly common stock stayed the same from Jun. 2025 (NT$1,393 Mil) to Sep. 2025 (NT$1,393 Mil) and stayed the same from Sep. 2025 (NT$1,393 Mil) to Dec. 2025 (NT$1,393 Mil).

Medigen Biotechnology's annual common stock declined from Dec. 2023 (NT$1,395 Mil) to Dec. 2024 (NT$1,393 Mil) but then stayed the same from Dec. 2024 (NT$1,393 Mil) to Dec. 2025 (NT$1,393 Mil).

Medigen Biotechnology Common Stock Historical Data

* Premium members only.

The historical data trend for Medigen Biotechnology's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology Common Stock Chart

Medigen Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,393.85 1,394.46 1,394.75 1,393.07 1,393.07

Medigen Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,393.07 1,393.07 1,393.07 1,393.07 1,393.07
ROCO:3176
54GF Score
Medigen Biotechnology Corp ROCO:3176
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Biotechnology Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of NT$1,393 Mil mean?
Medigen Biotechnology (ROCO:3176) has a Common Stock of NT$1,393 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's Common Stock too high?
Medigen Biotechnology's current Common Stock is NT$1,393 Mil. Overall, Medigen Biotechnology has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Common Stock compare to VRTX and REGN?
Medigen Biotechnology's Common Stock of NT$1,393 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current Common Stock is NT$1,393 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$49.78, compared to a current price of NT$34.15 — trading 31.4% below its estimated fair value. The current Common Stock is NT$1,393 Mil. Medigen Biotechnology's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Common Stock is NT$1,393 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued. The current stock price of NT$34.15 is trading 31.4% below its estimated GF Value™ of NT$49.78. GuruFocus considers Medigen Biotechnology to be Significantly Undervalued.

Key valuation signals for ROCO:3176:

  • Common Stock: NT$1,393 Mil
  • GF Value™: NT$49.78 vs. price of NT$34.15 (31.4% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
54GF Score

Get the complete analysis for ROCO:3176

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.15
Price
NT$49.78
GF Value